- Home
- PASG vs CTXR Comparison
PASG vs CTXR Comparison
Compare PASG & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- CTXR
- Stock Information
- Founded
- PASG 2017
- CTXR 2007
- Country
- PASG United States
- CTXR United States
- Employees
- PASG N/A
- CTXR N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- CTXR Health Care
- Exchange
- PASG Nasdaq
- CTXR Nasdaq
- Market Cap
- PASG 20.3M
- CTXR 20.8M
- IPO Year
- PASG 2020
- CTXR N/A
- Fundamental
- Price
- PASG $6.92
- CTXR $1.23
- Analyst Decision
- PASG Strong Buy
- CTXR Strong Buy
- Analyst Count
- PASG 4
- CTXR 3
- Target Price
- PASG $59.25
- CTXR $53.00
- AVG Volume (30 Days)
- PASG 31.7K
- CTXR 483.2K
- Earning Date
- PASG 08-12-2025
- CTXR 08-12-2025
- Dividend Yield
- PASG N/A
- CTXR N/A
- EPS Growth
- PASG N/A
- CTXR N/A
- EPS
- PASG N/A
- CTXR N/A
- Revenue
- PASG N/A
- CTXR N/A
- Revenue This Year
- PASG N/A
- CTXR N/A
- Revenue Next Year
- PASG N/A
- CTXR $851.67
- P/E Ratio
- PASG N/A
- CTXR N/A
- Revenue Growth
- PASG N/A
- CTXR N/A
- 52 Week Low
- PASG $5.12
- CTXR $0.65
- 52 Week High
- PASG $26.60
- CTXR $15.25
- Technical
- Relative Strength Index (RSI)
- PASG 49.95
- CTXR 44.57
- Support Level
- PASG $6.82
- CTXR $1.10
- Resistance Level
- PASG $7.63
- CTXR $1.57
- Average True Range (ATR)
- PASG 0.55
- CTXR 0.11
- MACD
- PASG -0.02
- CTXR -0.01
- Stochastic Oscillator
- PASG 25.89
- CTXR 26.49
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.